New immunotherapy company joining Peregrine's cancer-related companies portfolio. Ribon Therapeutics is a clinical-stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. Ribon Therapeutics is exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. The company is building a pipeline of selective, small molecule inhibitors t

New immunotherapy company joining Peregrine's cancer-related companies portfolio. Nectin is unlocking the power of the immune system by developing potent next-generation inhibitors targeting novel immune checkpoints, The company's Technology is based on Monoclonal antibodies and antibody-derived molecules that target the Nectin family of receptors and ligands. What differentiates Nectin from its competitors is its standalone efficacy as well as unprecedented synergy within th